{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:24:45Z","timestamp":1793913885803,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00808-z","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:35:19Z","timestamp":1763141719000},"page":"95-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-7019","authenticated-orcid":false,"given":"Christina","family":"Charles-Schoeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Zueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McDearmon-Blondell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siran","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanjinatus","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"808_CR1","doi-asserted-by":"crossref","unstructured":"Charles-Schoeman C, Zueger P, Blondell E, et al. Real-world analysis of initial clinical response and future outcomes among patients with rheumatoid arthritis initiating and remaining on a 1st-line tumor necrosis factor inhibitor in the United States. Arthritis Rheumatol. 2024;76(Suppl 9):Abstract 2674. https:\/\/acrabstracts.org\/abstract\/real-world-analysis-of-initial-clinical-response-and-future-outcomes-among-patients-with-rheumatoid-arthritis-initiating-and-remaining-on-a-1st-line-tumor-necrosis-factor-inhibitor-in-the-united-state\/","DOI":"10.1007\/s40744-025-00808-z"},{"issue":"3","key":"808_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","volume":"46","author":"LC Coates","year":"2016","unstructured":"Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum. 2016;46(3):291\u2013304.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"808_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.semarthrit.2020.10.010","volume":"51","author":"M Geijer","year":"2021","unstructured":"Geijer M, Alenius GM, Andr\u00e9 L, et al. Health-related quality of life in early psoriatic arthritis compared with early rheumatoid arthritis and a general population. Semin Arthritis Rheum. 2021;51(1):246\u201352.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"808_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"808_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"808_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Sch\u00fclke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.","journal-title":"Cells"},{"issue":"7","key":"808_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"808_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"808_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40744-020-00211-w","volume":"7","author":"E Sullivan","year":"2020","unstructured":"Sullivan E, Kershaw J, Blackburn S, Mahajan P, Boklage SH. Biologic disease-modifying antirheumatic drug prescription patterns among rheumatologists in Europe and Japan. Rheumatol Ther. 2020;7(3):517\u201335.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"808_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40744-020-00203-w","volume":"7","author":"E Sullivan","year":"2020","unstructured":"Sullivan E, Kershaw J, Blackburn S, Choi J, Curtis JR, Boklage S. Biologic disease-modifying antirheumatic drug prescription patterns for rheumatoid arthritis among United States physicians. Rheumatol Ther. 2020;7(2):383\u2013400.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"808_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/acr2.11621","volume":"6","author":"A Matsson","year":"2024","unstructured":"Matsson A, Solomon DH, Crabtree MM, Harrison RW, Litman HJ, Johansson FD. Patterns in the sequential treatment of patients with rheumatoid arthritis starting a biologic or targeted synthetic disease-modifying antirheumatic drug: 10-year experience from a US-based registry. ACR Open Rheumatol. 2024;6(1):5\u201313.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"808_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1366-1","volume":"19","author":"Y Jin","year":"2017","unstructured":"Jin Y, Desai RJ, Liu J, Choi NK, Kim SC. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):159.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"808_CR13","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/acr.22383","volume":"66","author":"JR Curtis","year":"2014","unstructured":"Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res. 2014;66(11):1604\u201311.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"808_CR14","first-page":"148","volume":"11","author":"DA Pappas","year":"2018","unstructured":"Pappas DA, Gerber RA, Litman HJ, et al. Delayed treatment acceleration in patients with rheumatoid arthritis who have inadequate response to initial tumor necrosis factor inhibitors: data from the Corrona registry. Am Heal drug benefits. 2018;11(3):148\u201358.","journal-title":"Am Heal drug benefits"},{"issue":"1","key":"808_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22\u201332.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"808_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Gorla R, et al. TNF-\u03b1 antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173(1):837\u201346.","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"808_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.autrev.2017.10.002","volume":"16","author":"EG Favalli","year":"2017","unstructured":"Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev. 2017;16(12):1185\u201395.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"808_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/acr2.11646","volume":"6","author":"C Edgerton","year":"2024","unstructured":"Edgerton C, Frick A, Helfgott S, et al. Real-world treatment and care patterns in patients with rheumatoid arthritis initiating first-line tumor necrosis factor inhibitor therapy in the United States. ACR Open Rheumatol. 2024;6(4):179\u201388.","journal-title":"ACR Open Rheumatol"},{"issue":"9","key":"808_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","volume":"32","author":"T Uhlig","year":"2014","unstructured":"Uhlig T, Moe RH, Kvien TK. The burden of disease in rheumatoid arthritis. Pharmacoeconomics. 2014;32(9):841\u201351.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"808_CR20","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/acr.24358","volume":"73","author":"ARK Matusevich","year":"2021","unstructured":"Matusevich ARK, Duan Z, Zhao H, et al. Treatment sequences after discontinuing a tumor necrosis factor inhibitor in patients with rheumatoid arthritis: a comparison of cycling versus swapping strategies. Arthritis Care Res. 2021;73(10):1461\u20139.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"808_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","volume":"20","author":"B Chastek","year":"2017","unstructured":"Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. J Med Econ. 2017;20(5):464\u201373.","journal-title":"J Med Econ"},{"issue":"5","key":"808_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s12272-014-0337-1","volume":"37","author":"HL Kim","year":"2014","unstructured":"Kim HL, Lee MY, Park SY, et al. Comparative effectiveness of cycling of tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-\u03b1 inhibitor using a Bayesian approach. Arch Pharm Res. 2014;37(5):662\u201370.","journal-title":"Arch Pharm Res"},{"issue":"10","key":"808_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/acr.22606","volume":"67","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, Yang S, Chen L, et al. Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients. Arthritis Care Res. 2015;67(10):1345\u201353.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"808_CR24","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56(10):3226\u201335.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"808_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/acr.20021","volume":"62","author":"LHD van Tuyl","year":"2010","unstructured":"van Tuyl LHD, Felson DT, Wells G, et al. Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res. 2010;62(1):108\u201317.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"808_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002658","volume":"8","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Fautrel B, Piette Y, et al. Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD Open. 2022;8(2):e002658.","journal-title":"RMD Open"},{"issue":"3","key":"808_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","volume":"15","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R. Treat-to-target in rheumatoid arthritis \u2014 are we there yet? Nat Rev Rheumatol. 2019;15(3):180\u20136.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"808_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091416","volume":"8","author":"B Batko","year":"2019","unstructured":"Batko B, Batko K, Krzanowski M, \u017buber Z. Physician adherence to treat-to-target and practice guidelines in rheumatoid arthritis. J Clin Med. 2019;8(9):1416.","journal-title":"J Clin Med"},{"issue":"4","key":"808_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/art.38323","volume":"66","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol. 2014;66(4):775\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"808_CR30","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1007\/s12325-023-02600-3","volume":"40","author":"J Dal\u00e9n","year":"2023","unstructured":"Dal\u00e9n J, Svedbom A, Hernlund E, Olofsson T, Black CM. Identifying predictors of first-line subcutaneous TNF-inhibitor persistence in patients with inflammatory arthritis: a decision tree analysis by indication. Adv Ther. 2023;40(10):4657\u201374.","journal-title":"Adv Ther"},{"issue":"12","key":"808_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102398","volume":"18","author":"A Rubbert-Roth","year":"2019","unstructured":"Rubbert-Roth A, Szab\u00f3 MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18(12):102398.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"808_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","volume":"13","author":"JR Kalden","year":"2017","unstructured":"Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13(12):707\u201318.","journal-title":"Nat Rev Rheumatol"},{"issue":"14","key":"808_CR33","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460\u20138.","journal-title":"JAMA"},{"issue":"6","key":"808_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","volume":"74","author":"GR Burmester","year":"2015","unstructured":"Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015;74(6):1037\u201344.","journal-title":"Ann Rheum Dis"},{"key":"808_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221114101","volume":"14","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Cerinic MM, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1759720X221114101.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"808_CR36","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.rdc.2009.10.008","volume":"35","author":"T Pincus","year":"2009","unstructured":"Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009;35(4):773\u20138.","journal-title":"Rheum Dis Clin North Am"},{"issue":"5 Suppl 39","key":"808_CR37","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100-8.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"808_CR38","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","volume":"38","author":"KJ Johnson","year":"2019","unstructured":"Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol. 2019;38(11):2967\u201376.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"808_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","volume":"4","author":"P Rein","year":"2017","unstructured":"Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4(2):247\u201361.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"808_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/mr\/road033","volume":"34","author":"R Caporali","year":"2023","unstructured":"Caporali R, Conti F, Iannone F. Management of patients with inflammatory rheumatic diseases after treatment failure with a first tumour necrosis factor inhibitor: a narrative review. Mod Rheumatol. 2023;34(1):11\u201326.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"808_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/acr.23859","volume":"72","author":"ARK Matusevich","year":"2020","unstructured":"Matusevich ARK, Suarez-Almazor ME, Cantor SB, Lal LS, Swint JM, Lopez-Olivo MA. Systematic review of economic evaluations of cycling versus swapping medications in patients with rheumatoid arthritis after failure to respond to tumor necrosis factor inhibitors. Arthritis Care Res. 2020;72(3):343\u201352.","journal-title":"Arthritis Care Res"},{"key":"808_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211002682","volume":"13","author":"A Migliore","year":"2021","unstructured":"Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211002682.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"808_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40744-024-00651-8","volume":"11","author":"L Bessette","year":"2024","unstructured":"Bessette L, Chan J, Chow A, et al. Real-world effectiveness of upadacitinib for treatment of rheumatoid arthritis in Canadian patients: interim results from the prospective observational CLOSE-UP study. Rheumatol Ther. 2024;11(3):563\u201382.","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00808-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00808-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00808-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:03:29Z","timestamp":1768838609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00808-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["808"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00808-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the completion of the manuscript, the affiliation of Dr. Manish Jain changed to Flourish Research, Chicago, IL, USA and Ravenswood Rheumatology, Chicago, IL, USA. Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Christina Charles-Schoeman: has received grant support from Priovant, CSL Behring, Janssen; grant support and consultant for Octapharma, Pfizer, AbbVie Inc., Bristol Myers Squibb; consultant for Boehringer Ingelheim, Recludix. Patrick Zueger: Employee of AbbVie Inc. and may hold stock or options. Erin McDearmon-Blondell: Employee of AbbVie Inc. and may hold stock or options. Siran Fang: Employee of AbbVie Inc. and may hold stock or options. Yi Peng: Employee of AbbVie Inc. and may hold stock or options. Tanjinatus Oishi: Employee of AbbVie Inc. and may hold stock or options. Manish Jain: has received grant\/research support from AbbVie Inc., Amgen, AnaptysBio, AstraZeneca, Bristol Myers Squibb, Celgene, Eli Lilly, Horizon, Janssen, Kolon TissueGene, LG Chem, Merck, Moderna, Novartis, Olatec, NIH, Pfizer, Selecta, and Shionogi. John Tesser: has received grant\/research support from AbbVie Inc., Alpine, Amgen, Arthrosi Therapeutics, Bendcare, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, CSL Behring, DRL, Eli Lilly, Emerald, Exagen, Genentech, Gilead, Global Health Living Foundation, Horizon, Janssen, Kolon TissueGene, Mitsubishi, Organogenesis, Pfizer, Samumed\/Biosplice, Selecta, SetPoint, Sun Pharma, Takeda, and Vorso; served on advisory boards or as a consultant for AbbVie Inc., Amgen, AstraZeneca, Aurinia, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Samumed\/Biosplice, Sanofi\/Genzyme, and UCB; speaker fees from AbbVie Inc., Amgen, Aurinia, AstraZeneca, Bristol Myers Squibb (through 2021), Eli Lilly, GlaxoSmithKline, Janssen, Pfizer, Sanofi\/Genzyme, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This was an observational research study which used a database of deidentified patient records for medical claims and electronic medical records. No interactions with patients occurred in the conduct of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}